Adynovi

rurioctocog alfa pegol · Baxalta Innovations GmbH
AUTHORISED IN THE EU

What Adynovi is used for

Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Adynovi
Active substance
rurioctocog alfa pegol
Disease area
Hemophilia A
Medicine group
Antihemorrhagics
ATC code
B02BD02
Marketing authorisation holder
Baxalta Innovations GmbH
Authorised in the EU since
2018

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Adynovi used for?

Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).

What is the active substance in Adynovi?

Adynovi contains rurioctocog alfa pegol.

Who makes Adynovi?

The EU marketing authorisation holder is Baxalta Innovations GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.